{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 4692, "items": [{"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T09:27:45Z", "timestamp": 1574328465216}, "reference-count": 30, "publisher": "Elsevier BV", "issue": "1-2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2010, 3, 1]], "date-time": "2010-03-01T00:00:00Z", "timestamp": 1267401600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Chemico-Biological Interactions"], "published-print": {"date-parts": [[2010, 3]]}, "DOI": "10.1016/j.cbi.2009.10.002", "type": "journal-article", "created": {"date-parts": [[2009, 10, 13]], "date-time": "2009-10-13T08:27:01Z", "timestamp": 1255422421000}, "page": "21-25", "source": "Crossref", "is-referenced-by-count": 9, "title": ["Micro-RNAs and copy number changes: New levels of gene regulation in acute myeloid leukemia"], "prefix": "10.1016", "volume": "184", "author": [{"given": "Richard A.", "family": "Larson", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Chemico-Biological Interactions"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0009279709004311?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0009279709004311?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 16]], "date-time": "2018-12-16T03:50:58Z", "timestamp": 1544932258000}, "score": 76.49201, "issued": {"date-parts": [[2010, 3]]}, "references-count": 30, "journal-issue": {"published-print": {"date-parts": [[2010, 3]]}, "issue": "1-2"}, "alternative-id": ["S0009279709004311"], "URL": "http://dx.doi.org/10.1016/j.cbi.2009.10.002", "ISSN": ["0009-2797"], "issn-type": [{"value": "0009-2797", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T18:36:40Z", "timestamp": 1574534200761}, "reference-count": 11, "publisher": "Springer Science and Business Media LLC", "issue": "4", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2001, 4, 1]], "date-time": "2001-04-01T00:00:00Z", "timestamp": 986083200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia"], "published-print": {"date-parts": [[2001, 4]]}, "DOI": "10.1038/sj.leu.2402064", "type": "journal-article", "created": {"date-parts": [[2011, 8, 11]], "date-time": "2011-08-11T10:32:51Z", "timestamp": 1313058771000}, "page": "675-676", "source": "Crossref", "is-referenced-by-count": 2, "title": ["New agents for induction and postremission therapy of acute myeloid leukemia"], "prefix": "10.1038", "volume": "15", "author": [{"given": "RA", "family": "Larson", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2001, 5, 1]]}, "reference": [{"key": "BF2402064_CR1", "doi-asserted-by": "publisher", "first-page": "1491", "DOI": "10.1038/sj.leu.2401522", "volume": "13", "author": "R Bouabdallah", "year": "1999", "unstructured": "Bouabdallah R, Lefrere F, Rose C et al. A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients Leukemia 1999 13: 1491\u20131496", "journal-title": "Leukemia"}, {"key": "BF2402064_CR2", "doi-asserted-by": "publisher", "first-page": "81", "DOI": "10.1023/A:1006216001681", "volume": "17", "author": "J Cortes", "year": "1999", "unstructured": "Cortes J, O'Brien S, Estey E, Giles F, Keating M, Kantarjian H . Phase I study of liposomal daunorubicin in patients with acute leukemia Invest New Drugs 1999 17: 81\u201387", "journal-title": "Invest New Drugs"}, {"key": "BF2402064_CR3", "first-page": "230b (Abstr)", "volume": "94", "author": "FJ Giles", "year": "1999", "unstructured": "Giles FJ, Cortes JE, Thomas DA et al. Troxacitabine (BCH-4556), a novel dioxolane nucleoside analog, has anti-leukemic activity Blood 1999 94: (Suppl. 1:2) 230b (Abstr)", "journal-title": "Blood"}, {"key": "BF2402064_CR4", "doi-asserted-by": "publisher", "first-page": "2193", "DOI": "10.1200/JCO.1994.12.10.2193", "volume": "12", "author": "EK Rowinsky", "year": "1994", "unstructured": "Rowinsky EK, Adjei A, Donehower RC et al. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia J Clin Oncol 1994 12: 2193\u20132203", "journal-title": "J Clin Oncol"}, {"key": "BF2402064_CR5", "doi-asserted-by": "publisher", "first-page": "521", "DOI": "10.3109/10428199809057611", "volume": "31", "author": "M Beran", "year": "1998", "unstructured": "Beran M, Estey E, O'Brien SM et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia Leuk Lymphoma 1998 31: 521\u2013531", "journal-title": "Leuk Lymphoma"}, {"key": "BF2402064_CR6", "doi-asserted-by": "publisher", "first-page": "2819", "DOI": "10.1200/JCO.1999.17.9.2819", "volume": "17", "author": "M Beran", "year": "1999", "unstructured": "Beran M, Estey E, O'Brien S et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia J Clin Oncol 1999 17: 2819\u20132830", "journal-title": "J Clin Oncol"}, {"key": "BF2402064_CR7", "doi-asserted-by": "publisher", "first-page": "479", "DOI": "10.3109/10428190009148395", "volume": "36", "author": "J Cortes", "year": "2000", "unstructured": "Cortes J, Estey E, Beran M et al. Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia Leuk Lymphoma 2000 36: 479\u2013484", "journal-title": "Leuk Lymphoma"}, {"key": "BF2402064_CR8", "first-page": "372", "volume": "6", "author": "JG Jurcic", "year": "2000", "unstructured": "Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA . Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia Clin Cancer Res 2000 6: 372\u2013380", "journal-title": "Clin Cancer Res"}, {"key": "BF2402064_CR9", "doi-asserted-by": "publisher", "first-page": "1436", "DOI": "10.1038/sj.leu.2401851", "volume": "14", "author": "K Naito", "year": "2000", "unstructured": "Naito K, Takeshita A, Shigeno K et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines Leukemia 2000 14: 1436\u20131443", "journal-title": "Leukemia"}, {"key": "BF2402064_CR10", "first-page": "3678", "volume": "93", "author": "EL Sievers", "year": "1999", "unstructured": "Sievers EL, Appelbaum FR, Spielberger RT et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate Blood 1999 93: 3678\u20133684", "journal-title": "Blood"}, {"key": "BF2402064_CR11", "unstructured": "Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of Mylotarg (gemtuzumab ozogamicin, CMA-676) in patients with CD33-positive acute myeloid leukemia in first relapse J Clin Oncol 2001 (in press)", "DOI": "10.1200/JCO.2001.19.13.3244", "doi-asserted-by": "crossref"}], "container-title": ["Leukemia"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/2402064.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/2402064", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/2402064.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 15]], "date-time": "2019-03-15T20:57:18Z", "timestamp": 1552683438000}, "score": 50.108364, "issued": {"date-parts": [[2001, 4]]}, "references-count": 11, "journal-issue": {"published-print": {"date-parts": [[2001, 4]]}, "issue": "4"}, "alternative-id": ["BF2402064"], "URL": "http://dx.doi.org/10.1038/sj.leu.2402064", "relation": {"cites": []}, "ISSN": ["0887-6924", "1476-5551"], "issn-type": [{"value": "0887-6924", "type": "print"}, {"value": "1476-5551", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:28:31Z", "timestamp": 1575530911434}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "3", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[1993, 8, 1]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>The translocation between chromosomes 8 and 21, t(8;21) (q22;q22), is the most frequent abnormality in acute myeloid leukemia (AML) with French-American-British type M2 (FAB-M2) morphology. The breakpoints in this translocation have been characterized at the molecular level, and the genes involved are AML1 on chromosome 21 and ETO on chromosome 8. The rearrangement of the two chromosomes results in a fusion gene and in the production of a consistent fusion transcript on the der(8) chromosome. We have used oligonucleotide primers derived from both sides of the fusion cDNA junction and reverse transcription-polymerase chain reaction (RT-PCR) to analyze six AML-M2 patients with a t(8;21) during various stages of their disease. Two patients studied at diagnosis and one studied at first relapse are alive off therapy and in continuous complete remission for 83 to 94 months. We have detected the AML/ETO fusion transcript in recent peripheral blood samples from each of them. Three other patients also had a fusion transcript detected after 1 to 4 months in remission. Two of these patients subsequently relapsed and died whereas the third patient is alive and in continuous complete remission 70 months later. Thus, our preliminary data suggest that cells with the translocation are still circulating in t(8;21) patients in long-term remission. This finding raises serious questions regarding the interpretation of positive results obtained only with this technique that may not be suitable to decide appropriate further treatment for patients in clinical remission.</jats:p>", "DOI": "10.1182/blood.v82.3.712.712", "type": "journal-article", "created": {"date-parts": [[2019, 10, 14]], "date-time": "2019-10-14T03:57:01Z", "timestamp": 1571025421000}, "page": "712-715", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 28, "title": ["Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission"], "prefix": "10.1182", "volume": "82", "author": [{"given": "G", "family": "Nucifora", "sequence": "first", "affiliation": [{"name": "Department of Medicine, University of Chicago, IL."}]}, {"given": "RA", "family": "Larson", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, University of Chicago, IL."}]}, {"given": "JD", "family": "Rowley", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, University of Chicago, IL."}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "http://ashpublications.org/blood/article-pdf/82/3/712/611318/712.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/blood/article-pdf/82/3/712/611318/712.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T07:07:32Z", "timestamp": 1574233652000}, "score": 34.313553, "issued": {"date-parts": [[1993, 8, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1993, 8, 1]]}, "issue": "3"}, "URL": "http://dx.doi.org/10.1182/blood.v82.3.712.712", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:19:26Z", "timestamp": 1575530366744}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "3", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[1993, 8, 1]]}, "abstract": "<jats:p>The translocation between chromosomes 8 and 21, t(8;21) (q22;q22), is the most frequent abnormality in acute myeloid leukemia (AML) with French-American-British type M2 (FAB-M2) morphology. The breakpoints in this translocation have been characterized at the molecular level, and the genes involved are AML1 on chromosome 21 and ETO on chromosome 8. The rearrangement of the two chromosomes results in a fusion gene and in the production of a consistent fusion transcript on the der(8) chromosome. We have used oligonucleotide primers derived from both sides of the fusion cDNA junction and reverse transcription-polymerase chain reaction (RT-PCR) to analyze six AML-M2 patients with a t(8;21) during various stages of their disease. Two patients studied at diagnosis and one studied at first relapse are alive off therapy and in continuous complete remission for 83 to 94 months. We have detected the AML/ETO fusion transcript in recent peripheral blood samples from each of them. Three other patients also had a fusion transcript detected after 1 to 4 months in remission. Two of these patients subsequently relapsed and died whereas the third patient is alive and in continuous complete remission 70 months later. Thus, our preliminary data suggest that cells with the translocation are still circulating in t(8;21) patients in long-term remission. This finding raises serious questions regarding the interpretation of positive results obtained only with this technique that may not be suitable to decide appropriate further treatment for patients in clinical remission.</jats:p>", "DOI": "10.1182/blood.v82.3.712.bloodjournal823712", "type": "journal-article", "created": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T08:07:38Z", "timestamp": 1570954058000}, "page": "712-715", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission"], "prefix": "10.1182", "volume": "82", "author": [{"given": "G", "family": "Nucifora", "sequence": "first", "affiliation": [{"name": "Department of Medicine, University of Chicago, IL."}]}, {"given": "RA", "family": "Larson", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, University of Chicago, IL."}]}, {"given": "JD", "family": "Rowley", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, University of Chicago, IL."}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "http://ashpublications.org/blood/article-pdf/82/3/712/230100/712.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/blood/article-pdf/82/3/712/230100/712.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T03:49:38Z", "timestamp": 1574221778000}, "score": 34.313553, "issued": {"date-parts": [[1993, 8, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1993, 8, 1]]}, "issue": "3"}, "URL": "http://dx.doi.org/10.1182/blood.v82.3.712.bloodjournal823712", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T10:12:10Z", "timestamp": 1574158330569}, "reference-count": 40, "publisher": "Springer Science and Business Media LLC", "issue": "3", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2003, 3, 1]], "date-time": "2003-03-01T00:00:00Z", "timestamp": 1046476800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia"], "published-print": {"date-parts": [[2003, 3]]}, "DOI": "10.1038/sj.leu.2402809", "type": "journal-article", "created": {"date-parts": [[2003, 3, 28]], "date-time": "2003-03-28T15:24:54Z", "timestamp": 1048865094000}, "page": "488-491", "source": "Crossref", "is-referenced-by-count": 8, "title": ["Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?"], "prefix": "10.1038", "volume": "17", "author": [{"given": "R A", "family": "Larson", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2003, 3, 19]]}, "reference": [{"key": "BF2402809_CR1", "unstructured": "Leith CP, Kopecky KJ, Godwin J . et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997; 89: 3323\u20133329."}, {"key": "BF2402809_CR2", "first-page": "1288", "volume": "82", "author": "DD Ross", "year": "1993", "unstructured": "Ross DD, Wooten PJ, Sridhara R, Ordonez JV, Lee EJ, Schiffer CA . Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 1993; 82: 1288\u20131299.", "journal-title": "Blood"}, {"key": "BF2402809_CR3", "first-page": "4226", "volume": "51", "author": "D Boesch", "year": "1991", "unstructured": "Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F . In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991; 51: 4226\u20134233.", "journal-title": "Cancer Res"}, {"key": "BF2402809_CR4", "doi-asserted-by": "publisher", "first-page": "1652", "DOI": "10.1200/JCO.1993.11.9.1652", "volume": "11", "author": "AF List", "year": "1993", "unstructured": "List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W . Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652\u20131660.", "journal-title": "J Clin Oncol"}, {"key": "BF2402809_CR5", "first-page": "787", "volume": "93", "author": "R Advani", "year": "1999", "unstructured": "Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL . Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 1999; 93: 787\u2013795.", "journal-title": "Blood"}, {"key": "BF2402809_CR6", "doi-asserted-by": "publisher", "first-page": "1867", "DOI": "10.1200/JCO.2000.18.9.1867", "volume": "18", "author": "GV Dahl", "year": "2000", "unstructured": "Dahl GV, Lacayo NJ, Brophy N, Dunussi-Joannopoulos K, Weinstein HJ, Chang M, Sikic BI, Arceci RJ . Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. J Clin Oncol 2000; 18: 1867\u20131875.", "journal-title": "J Clin Oncol"}, {"key": "BF2402809_CR7", "first-page": "566a", "volume": "90", "author": "P Sonneveld", "year": "1997", "unstructured": "Sonneveld P, Lowenberg B, Vossebeld P, Malkhandi J, Covelli A, Dekker AW, Ossenkoppwlw G, Milligan D, Verhoef G, Ferrant A, Yin J, Gratwohl A, Kovacsovis T, Burnett A . Dose-finding study of PSC833, a novel MDR reversing agent, with daunorubicin and ara-C in untreated elderly patients with acute myeloid leukemia. Blood 1997; 90: 566a.", "journal-title": "Blood"}, {"key": "BF2402809_CR8", "doi-asserted-by": "publisher", "first-page": "764", "DOI": "10.1038/sj.leu.2402117", "volume": "15", "author": "G Visani", "year": "2001", "unstructured": "Visani G, Milligan D, Leoni F, Chang J, Kelsey S, Marcus R, Powles R, Schey S, Covelli A, Isidori A, Litchman M, Piccaluga PP, Mayer H, Malagola M, Pfister C . Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. Leukemia 2001; 15: 764\u2013771.", "journal-title": "Leukemia"}, {"key": "BF2402809_CR9", "doi-asserted-by": "publisher", "first-page": "1589", "DOI": "10.1200/JCO.2001.19.6.1589", "volume": "19", "author": "R Dorr", "year": "2001", "unstructured": "Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore J, Weinberger B, Schiller G, Pearce T, Litchman M, Dalton W, Roe D, List AF . Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol 2001; 19: 1589\u20131599.", "journal-title": "J Clin Oncol"}, {"key": "BF2402809_CR10", "doi-asserted-by": "publisher", "first-page": "567", "DOI": "10.1016/S0145-2126(00)00024-2", "volume": "24", "author": "TR Chauncey", "year": "2000", "unstructured": "Chauncey TR, Rankin C, Anderson JE, Chen I, Kopecky KJ, Godwin JE, Kalaycio ME, Moore DF, Shurafa MS, Petersdorf SH, Kraut EH, Leith CP, Head DR, Luthardt FW, Willman CL, Appelbaum FR . A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group Study 9617. Leuk Res 2000; 24: 567\u2013574.", "journal-title": "Leuk Res"}, {"key": "BF2402809_CR11", "doi-asserted-by": "publisher", "first-page": "1796", "DOI": "10.1200/JCO.1997.15.5.1796", "volume": "15", "author": "SM Kornblau", "year": "1997", "unstructured": "Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M . Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 1997; 15: 1796\u20131802.", "journal-title": "J Clin Oncol"}, {"key": "BF2402809_CR12", "doi-asserted-by": "publisher", "first-page": "1837", "DOI": "10.1200/JCO.2000.18.9.1837", "volume": "18", "author": "U Tidefelt", "year": "2000", "unstructured": "Tidefelt U, Liliemark J, Gruber A, Liliemark E, Sundman-Engberg B, Juliusson G, Stenke L, Elmhorn-Rosenborg A, Mollgard L, Lehman S, Xu D, Covelli A, Gustavsson B, Paul C . P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J Clin Oncol 2000; 18: 1837\u20131844.", "journal-title": "J Clin Oncol"}, {"key": "BF2402809_CR13", "doi-asserted-by": "publisher", "first-page": "358", "DOI": "10.1002/(SICI)1097-0142(19990115)85:2<358::AID-CNCR13>3.0.CO;2-0", "volume": "85", "author": "MS Tallman", "year": "1999", "unstructured": "Tallman MS, Lee S, Sikic BI, Paietta E, Wiernik PH, Bennett JM, Rowe JM . Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study. Cancer 1999; 85: 358\u2013367.", "journal-title": "Cancer"}, {"key": "BF2402809_CR14", "first-page": "383a", "volume": "94", "author": "P Greenberg", "year": "1999", "unstructured": "Greenberg P, Advani R, Tallman M, Letendre L, Saba H, Dugan K, Lee SJ, Lum B, Sikic BI, Paietta E, Bennett J, Rowe JM . Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: randomized Phase III trial (E2995). Blood 1999; 94: 383a.", "journal-title": "Blood"}, {"key": "BF2402809_CR15", "first-page": "1198", "volume": "88", "author": "E Solary", "year": "1996", "unstructured": "Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn JY, Sadoun A, Pignon B, Berthou C, Maloisel F, Guyotat D, Casassus P, Ifrah N, Lamy Y, Audhuy B, Colombat P, Harousseau JL . Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 1996; 88: 1198\u20131205.", "journal-title": "Blood"}, {"key": "BF2402809_CR16", "doi-asserted-by": "publisher", "first-page": "713", "DOI": "10.1046/j.1365-2141.2001.02785.x", "volume": "113", "author": "JA Liu Yin", "year": "2001", "unstructured": "Liu Yin JA, Wheatley K, Rees JK, Burnett AK . Comparison of \u2018sequential\u2019 versus \u2018standard\u2019 chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 2001; 113: 713\u2013726.", "journal-title": "Br J Haematol"}, {"key": "BF2402809_CR17", "first-page": "1224", "volume": "100", "author": "MR Baer", "year": "2002", "unstructured": "Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, Bloomfield CD, Larson RA . Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002; 100: 1224\u20131232.", "journal-title": "Blood"}, {"key": "BF2402809_CR18", "doi-asserted-by": "publisher", "first-page": "3212", "DOI": "10.1182/blood.V98.12.3212", "volume": "98", "author": "AF List", "year": "2001", "unstructured": "List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, Dorr R, Karanes C, Hynes HE, Doroshow JH, Shurafa M, Appelbaum FR . Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group Study. Blood 2001; 98: 3212\u20133220.", "journal-title": "Blood"}, {"key": "BF2402809_CR19", "doi-asserted-by": "publisher", "first-page": "505", "DOI": "10.1038/sj.leu.2400984", "volume": "12", "author": "LM Pilarski", "year": "1998", "unstructured": "Pilarski LM, Yatscoff RW, Murphy GF, Belch AR . Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers. Leukemia 1998; 12: 505\u2013509.", "journal-title": "Leukemia"}, {"key": "BF2402809_CR20", "doi-asserted-by": "publisher", "first-page": "637", "DOI": "10.1038/sj.bmt.1701942", "volume": "24", "author": "G Vogelsang", "year": "1999", "unstructured": "Vogelsang G, Bitton R, Piantadosi S, Altomonte V, Horn T, Jones R, Miller C, Marcellus D, Abrams R, Hess A . Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial. Bone Marrow Transplant 1999; 24: 637\u2013640.", "journal-title": "Bone Marrow Transplant"}, {"key": "BF2402809_CR21", "first-page": "3157", "volume": "82", "author": "PA te Boekhorst", "year": "1993", "unstructured": "te Boekhorst PA, de Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeijer A, Lowenberg B, Sonneveld P . Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 1993; 82: 3157\u20133162.", "journal-title": "Blood"}, {"key": "BF2402809_CR22", "doi-asserted-by": "publisher", "first-page": "76", "DOI": "10.1046/j.1365-2141.1997.3343148.x", "volume": "99", "author": "MM van den Heuvel-Eibrink", "year": "1997", "unstructured": "van den Heuvel-Eibrink MM, van der HB, te Boekhorst PA, Pieters R, Schoester M, Lowenberg B, Sonneveld P . MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br J Haematol 1997; 99: 76\u201383.", "journal-title": "Br J Haematol"}, {"key": "BF2402809_CR23", "doi-asserted-by": "publisher", "first-page": "175", "DOI": "10.1016/0145-2126(95)00134-4", "volume": "20", "author": "A Samdani", "year": "1996", "unstructured": "Samdani A, Vijapurkar U, Grimm MA, Spier CS, Grogan TM, Glinsmann-Gibson BJ, List AF . Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leuk Res 1996; 20: 175\u2013180.", "journal-title": "Leuk Res"}, {"key": "BF2402809_CR24", "first-page": "711", "volume": "85", "author": "C Wuchter", "year": "2000", "unstructured": "Wuchter C, Leonid K, Ruppert V, Schrappe M, Buchner T, Schoch C, Haferlach T, Harbott J, Ratei R, Dorken B, Ludwig WD . Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000; 85: 711\u2013721.", "journal-title": "Haematologica"}, {"key": "BF2402809_CR25", "first-page": "1086", "volume": "94", "author": "CP Leith", "year": "1999", "unstructured": "Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL . Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999; 94: 1086\u20131099.", "journal-title": "Blood"}, {"key": "BF2402809_CR26", "first-page": "103", "volume": "243", "author": "AM Oza", "year": "2002", "unstructured": "Oza AM . Clinical development of P glycoprotein modulators in oncology. Novartis Found Symp 2002; 243: 103\u2013115.", "journal-title": "Novartis Found Symp"}, {"key": "BF2402809_CR27", "doi-asserted-by": "publisher", "first-page": "3130", "DOI": "10.1200/JCO.2001.19.12.3130", "volume": "19", "author": "RA Peck", "year": "2001", "unstructured": "Peck RA, Hewett J, Harding MW, Wang YM, Chaturvedi PR, Bhatnagar A, Ziessman H, Atkins F, Hawkins MJ . Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 2001; 19: 3130\u20133141.", "journal-title": "J Clin Oncol"}, {"key": "BF2402809_CR28", "unstructured": "Slapak CA, Dahlheimer J, Piwnica-Worms D . Reversal of multidrug resistance with LY335979: functional analysis of p-glycoprotein-mediated transport activity and its modulation in vivo. J Clin Pharmacol 2001; (Suppl): 29S\u201338S.", "DOI": "10.1177/009127001773744134", "doi-asserted-by": "crossref"}, {"key": "BF2402809_CR29", "first-page": "384a", "volume": "94", "author": "JE Kolitz", "year": "1999", "unstructured": "Kolitz JE, George SL, Hurd DD, Hoke E, Dodge RK, Velez-Garcia E, Powell BL, Moore J, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA . Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients with acute myeloid leukemia (AML) &lt;60 years old: preliminary results of CALGB 9621. Blood 1999; 94: 384a.", "journal-title": "Blood"}, {"key": "BF2402809_CR30", "first-page": "461a", "volume": "98", "author": "JE Kolitz", "year": "2001", "unstructured": "Kolitz JE, George SL, Dodge RK, Hoke E, Hurd DD, Powell BL, Velejz-Garcia E, Caligiuri MA, Moore JO, Vardiman JW, Bloomfield CD, Larson RA . Dose escalation studies of Ara-C (A), daunorubicin (D) and etoposide (E) with and without multidrug resistance (MDR) modulation with PSC-833 (P) in untreated adults with acute myeloid leukemia (AML) &lt;60 years: final induction results of CALGB 9621. Blood 2001; 98: 461a (abstract).", "journal-title": "Blood"}, {"key": "BF2402809_CR31", "doi-asserted-by": "publisher", "first-page": "610", "DOI": "10.1200/JCO.1996.14.2.610", "volume": "14", "author": "DJ Boote", "year": "1996", "unstructured": "Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM . Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996; 14: 610\u2013618.", "journal-title": "J Clin Oncol"}, {"key": "BF2402809_CR32", "doi-asserted-by": "publisher", "first-page": "688a", "DOI": "10.1182/blood.V98.3.688", "volume": "98", "author": "JE Kolitz", "year": "2001", "unstructured": "Kolitz JE, George SL, Dodge RK, Hoke E, Hurd DD, Powell BL, Velez-Garcia E, Caligiuri MA, Moore JO, Vardiman JW, Linker CA, Bloomfield CD, Larson RA . Consolidation therapy by cytogenetic risk in adults with AML &lt;60 years in first complete remission. Blood 2001; 98: 688a.", "journal-title": "Blood"}, {"key": "BF2402809_CR33", "first-page": "689a", "volume": "98", "author": "C Linker", "year": "2001", "unstructured": "Linker C, George S, Hurd DD, Larson RA . Autologous stem cell transplantation for acute myeloid leukemia in second remission. Blood 2001; 98: 689a.", "journal-title": "Blood"}, {"key": "BF2402809_CR34", "first-page": "76a", "volume": "95", "author": "MA Caligiuri", "year": "1999", "unstructured": "Caligiuri MA, Lee EJ, Baer MR, Dodge RK, Cooke K, Szatrowski T, Bloomfield CD, Larson RA . Daily low dose interleukin-2 therapy with or without intermediate dose pulsing in acute myeloid leukemia patients &gt;60 years old in first complete remission: a feasibility study (CALGB 9420). Blood 1999; 95: 76a.", "journal-title": "Blood"}, {"key": "BF2402809_CR35", "doi-asserted-by": "publisher", "first-page": "2831", "DOI": "10.1200/JCO.1999.17.9.2831", "volume": "17", "author": "EJ Lee", "year": "1999", "unstructured": "Lee EJ, George SL, Caligiuri M, Szatrowski TP, Powell BL, Lemke S, Dodge RK, Smith R, Baer M, Schiffer CA . Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420. J Clin Oncol 1999; 17: 2831\u20132839.", "journal-title": "J Clin Oncol"}, {"key": "BF2402809_CR36", "doi-asserted-by": "publisher", "first-page": "896", "DOI": "10.1056/NEJM199410063311402", "volume": "331", "author": "RJ Mayer", "year": "1994", "unstructured": "Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei III E, Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896\u2013903.", "journal-title": "N Engl J Med"}, {"key": "BF2402809_CR37", "doi-asserted-by": "publisher", "first-page": "1671", "DOI": "10.1056/NEJM199506223322503", "volume": "332", "author": "RM Stone", "year": "1995", "unstructured": "Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA . Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995; 332: 1671\u20131677.", "journal-title": "N Engl J Med"}, {"key": "BF2402809_CR38", "doi-asserted-by": "publisher", "first-page": "24", "DOI": "10.1097/00001622-200201000-00005", "volume": "14", "author": "MA Sekeres", "year": "2002", "unstructured": "Sekeres MA, Stone RM . The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol 2002; 14: 24\u201330.", "journal-title": "Curr Opin Oncol"}, {"key": "BF2402809_CR39", "first-page": "2329", "volume": "86", "author": "CP Leith", "year": "1995", "unstructured": "Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL . Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR\u2212/efflux+ and MDR1/efflux\u2212 cases. Blood 1995; 86: 2329\u20132342.", "journal-title": "Blood"}, {"key": "BF2402809_CR40", "doi-asserted-by": "publisher", "first-page": "14", "DOI": "10.1002/(SICI)1097-0320(19960901)25:1<14::AID-CYTO2>3.0.CO;2-E", "volume": "25", "author": "H Minderman", "year": "1996", "unstructured": "Minderman H, Vanhoefer U, Toth K, Yin MB, Minderman MD, Wrzosek C, Slovak ML, Rustum YM . DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux. Cytometry 1996; 25: 14\u201320.", "journal-title": "Cytometry"}], "container-title": ["Leukemia"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/2402809.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/2402809", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/2402809.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 17]], "date-time": "2019-03-17T06:17:51Z", "timestamp": 1552803471000}, "score": 33.757523, "issued": {"date-parts": [[2003, 3]]}, "references-count": 40, "journal-issue": {"published-print": {"date-parts": [[2003, 3]]}, "issue": "3"}, "alternative-id": ["BF2402809"], "URL": "http://dx.doi.org/10.1038/sj.leu.2402809", "relation": {"cites": []}, "ISSN": ["0887-6924", "1476-5551"], "issn-type": [{"value": "0887-6924", "type": "print"}, {"value": "1476-5551", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T10:30:14Z", "timestamp": 1574332214075}, "reference-count": 10, "publisher": "Informa UK Limited", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia & Lymphoma"], "published-print": {"date-parts": [[1991, 1]]}, "DOI": "10.3109/10428199109068058", "type": "journal-article", "created": {"date-parts": [[2007, 11, 23]], "date-time": "2007-11-23T15:33:44Z", "timestamp": 1195832024000}, "page": "145-148", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Neurocysticercosis Coincident with Acute Myeloid Leukemia: A Case Report"], "prefix": "10.1080", "volume": "4", "author": [{"given": "Wendy", "family": "Stock", "sequence": "first", "affiliation": []}, {"given": "Richard A.", "family": "Larson", "sequence": "additional", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2009, 7]]}, "reference": [{"key": "CIT0001", "DOI": "10.1056/NEJM198404193101601", "doi-asserted-by": "publisher"}, {"key": "CIT0002", "DOI": "10.1016/S0140-6736(89)91268-3", "doi-asserted-by": "publisher"}, {"key": "CIT0003", "DOI": "10.1056/NEJM198412063112307", "doi-asserted-by": "publisher"}, {"key": "CIT0004", "author": "VanDellen J. R.", "volume": "22", "first-page": "92", "year": "1988", "journal-title": "Neurosurg", "DOI": "10.1227/00006123-198801000-00015", "doi-asserted-by": "crossref"}, {"key": "CIT0005", "DOI": "10.1001/archneur.1988.00520290064015", "doi-asserted-by": "publisher"}, {"key": "CIT0006", "author": "Gardner B.", "volume": "34", "first-page": "56", "year": "1984", "journal-title": "Neurology"}, {"key": "CIT0007", "author": "Ciferri F", "volume": "311", "first-page": "733", "year": "1984", "journal-title": "N. Engl. J. Med"}, {"key": "CIT0008", "DOI": "10.7326/0003-4819-99-2-179", "doi-asserted-by": "publisher"}, {"key": "CIT0009", "author": "Mitchell W. G.", "volume": "82", "first-page": "76", "year": "1988", "journal-title": "Pediatrics"}, {"key": "CIT0010", "DOI": "10.1212/WNL.33.10.1377", "doi-asserted-by": "publisher"}], "container-title": ["Leukemia & Lymphoma"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.3109/10428199109068058", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 18]], "date-time": "2017-06-18T01:12:26Z", "timestamp": 1497748346000}, "score": 33.042717, "issued": {"date-parts": [[1991, 1]]}, "references-count": 10, "journal-issue": {"published-online": {"date-parts": [[2009, 7]]}, "published-print": {"date-parts": [[1991, 1]]}, "issue": "2"}, "alternative-id": ["10.3109/10428199109068058"], "URL": "http://dx.doi.org/10.3109/10428199109068058", "relation": {"cites": []}, "ISSN": ["1042-8194", "1029-2403"], "issn-type": [{"value": "1042-8194", "type": "print"}, {"value": "1029-2403", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T08:14:20Z", "timestamp": 1574496860830}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2010, 4, 15]]}, "DOI": "10.1158/1538-7445.am10-4080", "type": "proceedings-article", "created": {"date-parts": [[2011, 2, 25]], "date-time": "2011-02-25T18:05:46Z", "timestamp": 1298657146000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract 4080: Global changes in gene expression during phorbol ester-induced differentiation of human acute myeloid leukemia cells"], "prefix": "10.1158", "author": [{"given": "Emily", "family": "Swain", "sequence": "first", "affiliation": []}, {"given": "Adnan", "family": "Solaiman", "sequence": "additional", "affiliation": []}, {"given": "Senaka", "family": "Ratnayake", "sequence": "additional", "affiliation": []}, {"given": "Abby", "family": "Larson", "sequence": "additional", "affiliation": []}, {"given": "Ryan", "family": "Deeds", "sequence": "additional", "affiliation": []}, {"given": "Amy", "family": "Conner", "sequence": "additional", "affiliation": []}, {"given": "Jeffrey", "family": "Forrester", "sequence": "additional", "affiliation": []}, {"given": "Michael", "family": "Roberts", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 11, 17]]}, "event": {"name": "Proceedings: AACR 101st Annual Meeting 2010\u2010\u2010 Apr 17\u201021, 2010; Washington, DC"}, "container-title": ["Cellular and Molecular Biology"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.AM10-4080", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T17:24:35Z", "timestamp": 1558200275000}, "score": 32.299793, "issued": {"date-parts": [[2010, 4, 15]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.AM10-4080"], "URL": "http://dx.doi.org/10.1158/1538-7445.am10-4080"}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T19:39:18Z", "timestamp": 1574278758740}, "publisher-location": "Oxford, UK", "reference-count": 0, "publisher": "Wiley-Blackwell", "isbn-type": [{"value": "9781405157476", "type": "print"}, {"value": "9781444300857", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1002/9781444300857.ch34", "type": "book-chapter", "created": {"date-parts": [[2009, 2, 4]], "date-time": "2009-02-04T10:47:53Z", "timestamp": 1233744473000}, "page": "278-286", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Acute Myeloid Leukemia in Adults: Postremission Therapy"], "prefix": "10.1002", "author": [{"given": "Cara A.", "family": "Rosenbaum", "sequence": "first", "affiliation": []}, {"given": "Richard A.", "family": "Larson", "sequence": "additional", "affiliation": []}], "member": "311", "container-title": ["Evidence-Based Hematology"], "link": [{"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/9781444300857.ch34", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 5]], "date-time": "2018-08-05T09:27:27Z", "timestamp": 1533461247000}, "score": 30.745869, "issued": {"date-parts": [[null]]}, "ISBN": ["9781444300857", "9781405157476"], "references-count": 0, "URL": "http://dx.doi.org/10.1002/9781444300857.ch34"}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T09:51:10Z", "timestamp": 1574243470740}, "reference-count": 0, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Current Opinion in Oncology"], "published-print": {"date-parts": [[1991, 2]]}, "DOI": "10.1097/00001622-199102000-00005", "type": "journal-article", "created": {"date-parts": [[2006, 11, 8]], "date-time": "2006-11-08T09:25:27Z", "timestamp": 1162977927000}, "page": "30-38", "source": "Crossref", "is-referenced-by-count": 4, "title": ["Therapy for acute myeloid leukemia and acute lymphoblastic leukemia in adults"], "prefix": "10.1097", "volume": "3", "author": [{"given": "Robert B.", "family": "Geller", "sequence": "first", "affiliation": []}, {"given": "Richard A.", "family": "Larson", "sequence": "additional", "affiliation": []}], "member": "276", "container-title": ["Current Opinion in Oncology"], "language": "en", "deposited": {"date-parts": [[2018, 2, 8]], "date-time": "2018-02-08T20:49:16Z", "timestamp": 1518122956000}, "score": 29.99678, "subtitle": [""], "issued": {"date-parts": [[1991, 2]]}, "references-count": 0, "journal-issue": {"issue": "1"}, "URL": "http://dx.doi.org/10.1097/00001622-199102000-00005", "ISSN": ["1040-8746"], "issn-type": [{"value": "1040-8746", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T18:51:03Z", "timestamp": 1574275863408}, "reference-count": 23, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2007, 3, 1]], "date-time": "2007-03-01T00:00:00Z", "timestamp": 1172707200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Best Practice & Research Clinical Haematology"], "published-print": {"date-parts": [[2007, 3]]}, "DOI": "10.1016/j.beha.2006.10.006", "type": "journal-article", "created": {"date-parts": [[2007, 3, 1]], "date-time": "2007-03-01T21:29:55Z", "timestamp": 1172784595000}, "page": "29-37", "source": "Crossref", "is-referenced-by-count": 42, "title": ["Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?"], "prefix": "10.1016", "volume": "20", "author": [{"given": "Richard A.", "family": "Larson", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Best Practice & Research Clinical Haematology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1521692606000752?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1521692606000752?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 25]], "date-time": "2019-04-25T01:31:26Z", "timestamp": 1556155886000}, "score": 29.62542, "issued": {"date-parts": [[2007, 3]]}, "references-count": 23, "journal-issue": {"published-print": {"date-parts": [[2007, 3]]}, "issue": "1"}, "alternative-id": ["S1521692606000752"], "URL": "http://dx.doi.org/10.1016/j.beha.2006.10.006", "ISSN": ["1521-6926"], "issn-type": [{"value": "1521-6926", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T02:17:53Z", "timestamp": 1574302673371}, "reference-count": 17, "publisher": "Informa Healthcare", "issue": "8", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Expert Opinion on Pharmacotherapy"], "published-print": {"date-parts": [[2009, 6]]}, "DOI": "10.1517/14656560902997990", "type": "journal-article", "created": {"date-parts": [[2009, 5, 23]], "date-time": "2009-05-23T13:07:23Z", "timestamp": 1243084043000}, "page": "1353-1357", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Clofarabine: a new treatment option for patients with acute myeloid leukemia"], "prefix": "10.1517", "volume": "10", "author": [{"given": "Melissa L", "family": "Larson", "sequence": "first", "affiliation": []}, {"given": "Parameswaran", "family": "Venugopal", "sequence": "additional", "affiliation": []}], "member": "3197", "published-online": {"date-parts": [[2009, 5, 23]]}, "reference": [{"key": "CIT0002", "author": "Appelbaum", "volume": "107", "first-page": "3481", "year": "2006", "journal-title": "Blood", "DOI": "10.1182/blood-2005-09-3724", "doi-asserted-by": "crossref"}, {"key": "CIT0003", "author": "Leith", "volume": "89", "first-page": "3323", "year": "1997", "journal-title": "Blood"}, {"key": "CIT0004", "author": "Leith", "volume": "94", "first-page": "1086", "year": "1999", "journal-title": "Blood"}, {"key": "CIT0005", "DOI": "10.1001/archinte.162.14.1597", "doi-asserted-by": "publisher"}, {"key": "CIT0006", "author": "Estey", "volume": "25", "first-page": "1908", "year": "2007", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2006.10.2731", "doi-asserted-by": "crossref"}, {"key": "CIT0007", "author": "Rowe", "volume": "86", "first-page": "457", "year": "1995", "journal-title": "Blood"}, {"key": "CIT0008", "author": "Mayer", "volume": "331", "first-page": "896", "year": "1994", "journal-title": "N Engl J Med", "DOI": "10.1056/NEJM199410063311402", "doi-asserted-by": "crossref"}, {"key": "CIT0009", "author": "Kantarjian", "volume": "48", "first-page": "1922", "year": "2007", "journal-title": "Leuk Lymph", "DOI": "10.1080/10428190701545644", "doi-asserted-by": "crossref"}, {"key": "CIT0010", "DOI": "10.1182/blood-2004-05-1933", "doi-asserted-by": "publisher"}, {"key": "CIT0011", "author": "Kantarjian", "volume": "21", "first-page": "1167", "year": "2003", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2003.04.031", "doi-asserted-by": "crossref"}, {"key": "CIT0012", "DOI": "10.1182/blood-2003-03-0925", "doi-asserted-by": "publisher"}, {"key": "CIT0013", "author": "Burnett", "volume": "104", "first-page": "248a", "year": "2004", "journal-title": "Blood"}, {"key": "CIT0014", "author": "Burnett", "volume": "108", "first-page": "130a", "year": "2006", "journal-title": "Blood"}, {"key": "CIT0015", "DOI": "10.1002/cncr.22496", "doi-asserted-by": "publisher"}, {"key": "CIT0016", "author": "Erba", "volume": "112", "first-page": "209", "year": "2008", "journal-title": "Blood", "DOI": "10.1182/blood-2008-04-151340", "doi-asserted-by": "crossref"}, {"key": "CIT0017", "DOI": "10.1182/blood-2005-08-3294", "doi-asserted-by": "publisher"}, {"key": "CIT0018", "DOI": "10.1182/blood-2007-11-124602", "doi-asserted-by": "publisher"}], "container-title": ["Expert Opinion on Pharmacotherapy"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.1517/14656560902997990", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 18]], "date-time": "2017-06-18T20:13:43Z", "timestamp": 1497816823000}, "score": 29.61512, "issued": {"date-parts": [[2009, 5, 23]]}, "references-count": 17, "journal-issue": {"published-online": {"date-parts": [[2009, 5, 23]]}, "published-print": {"date-parts": [[2009, 6]]}, "issue": "8"}, "alternative-id": ["10.1517/14656560902997990"], "URL": "http://dx.doi.org/10.1517/14656560902997990", "relation": {"cites": []}, "ISSN": ["1465-6566", "1744-7666"], "issn-type": [{"value": "1465-6566", "type": "print"}, {"value": "1744-7666", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T21:38:43Z", "timestamp": 1574113123435}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "5", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[1998, 5, 1]], "date-time": "1998-05-01T00:00:00Z", "timestamp": 893980800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia"], "published-print": {"date-parts": [[1998, 5]]}, "DOI": "10.1038/sj.leu.2401007", "type": "journal-article", "created": {"date-parts": [[2002, 9, 4]], "date-time": "2002-09-04T18:30:16Z", "timestamp": 1031164216000}, "page": "660-665", "source": "Crossref", "is-referenced-by-count": 59, "title": ["Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia"], "prefix": "10.1038", "volume": "12", "author": [{"given": "RA", "family": "Larson", "sequence": "first", "affiliation": []}, {"given": "MH", "family": "Fretzin", "sequence": "additional", "affiliation": []}, {"given": "RK", "family": "Dodge", "sequence": "additional", "affiliation": []}, {"given": "CA", "family": "Schiffer", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[1998, 5, 29]]}, "container-title": ["Leukemia"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/2401007.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/2401007", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/2401007.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 16]], "date-time": "2019-03-16T07:00:42Z", "timestamp": 1552719642000}, "score": 28.864578, "issued": {"date-parts": [[1998, 5]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1998, 5]]}, "issue": "5"}, "alternative-id": ["BF2401007"], "URL": "http://dx.doi.org/10.1038/sj.leu.2401007", "ISSN": ["0887-6924", "1476-5551"], "issn-type": [{"value": "0887-6924", "type": "print"}, {"value": "1476-5551", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T19:39:18Z", "timestamp": 1574278758751}, "publisher-location": "Oxford, UK", "reference-count": 0, "publisher": "Wiley-Blackwell", "isbn-type": [{"value": "9781405157476", "type": "print"}, {"value": "9781444300857", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1002/9781444300857.ch33", "type": "book-chapter", "created": {"date-parts": [[2009, 2, 4]], "date-time": "2009-02-04T10:47:53Z", "timestamp": 1233744473000}, "page": "268-277", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Acute Myeloid Leukemia in Adults: Remission Induction Therapy"], "prefix": "10.1002", "author": [{"given": "Cara A.", "family": "Rosenbaum", "sequence": "first", "affiliation": []}, {"given": "Richard A.", "family": "Larson", "sequence": "additional", "affiliation": []}], "member": "311", "container-title": ["Evidence-Based Hematology"], "link": [{"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/9781444300857.ch33", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 5]], "date-time": "2018-08-05T09:27:22Z", "timestamp": 1533461242000}, "score": 28.454727, "issued": {"date-parts": [[null]]}, "ISBN": ["9781444300857", "9781405157476"], "references-count": 0, "URL": "http://dx.doi.org/10.1002/9781444300857.ch33"}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T17:26:13Z", "timestamp": 1575221173156}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2013, 5, 1]], "date-time": "2013-05-01T00:00:00Z", "timestamp": 1367366400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia Research"], "published-print": {"date-parts": [[2013, 5]]}, "DOI": "10.1016/s0145-2126(13)70022-5", "type": "journal-article", "created": {"date-parts": [[2013, 5, 9]], "date-time": "2013-05-09T07:33:29Z", "timestamp": 1368084809000}, "page": "S7-S8", "source": "Crossref", "is-referenced-by-count": 0, "title": ["I-020 The syndrome of therapy-related myeloid neoplasms"], "prefix": "10.1016", "volume": "37", "author": [{"given": "R.A.", "family": "Larson", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Leukemia Research"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0145212613700225?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0145212613700225?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 16]], "date-time": "2018-10-16T04:27:51Z", "timestamp": 1539664071000}, "score": 27.955887, "issued": {"date-parts": [[2013, 5]]}, "references-count": 0, "alternative-id": ["S0145212613700225"], "URL": "http://dx.doi.org/10.1016/s0145-2126(13)70022-5", "ISSN": ["0145-2126"], "issn-type": [{"value": "0145-2126", "type": "print"}], "subject": ["Cancer Research", "Oncology", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:25:35Z", "timestamp": 1575530735571}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "10", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[1992, 11, 15]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Ten patients with active acute myelogenous leukemia (AML) received either 13 cis retinoic acid (RA) + alpha interferon (IFN) or recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) for 3 days. Cell cycle measurements were performed before and at the conclusion of administration of the bioactive agent(s). The proliferative rate of the leukemia cells in vivo decreased in four of five patients receiving RA+IFN whereas in one patient proliferation accelerated. The proliferative rate of AML cells accelerated in three of the five patients who received rhGM-CSF and slowed in two patients. These data show that while the proliferative rate of AML cells can be altered in vivo, the effect produced by bioactive agents may be the opposite of the desired effect. Furthermore, the studies described here demonstrate the usefulness of marrow biopsies for measuring the percent S-phase cells and the importance of measuring the duration of S phase so that the effects of bioactive agents on the cell cycle time of the leukemia cells can be determined.</jats:p>", "DOI": "10.1182/blood.v80.10.2600.2600", "type": "journal-article", "created": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T21:38:26Z", "timestamp": 1571002706000}, "page": "2600-2603", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients"], "prefix": "10.1182", "volume": "80", "author": [{"given": "HD", "family": "Preisler", "sequence": "first", "affiliation": [{"name": "Department of Internal Medicine, University of Cincinnati, OH."}]}, {"given": "A", "family": "Raza", "sequence": "additional", "affiliation": [{"name": "Department of Internal Medicine, University of Cincinnati, OH."}]}, {"given": "RA", "family": "Larson", "sequence": "additional", "affiliation": [{"name": "Department of Internal Medicine, University of Cincinnati, OH."}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "http://ashpublications.org/blood/article-pdf/80/10/2600/608314/2600.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/blood/article-pdf/80/10/2600/608314/2600.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T06:01:12Z", "timestamp": 1574229672000}, "score": 27.479233, "issued": {"date-parts": [[1992, 11, 15]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1992, 11, 15]]}, "issue": "10"}, "URL": "http://dx.doi.org/10.1182/blood.v80.10.2600.2600", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:18:35Z", "timestamp": 1575530315476}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "10", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[1992, 11, 15]]}, "abstract": "<jats:p>Ten patients with active acute myelogenous leukemia (AML) received either 13 cis retinoic acid (RA) + alpha interferon (IFN) or recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) for 3 days. Cell cycle measurements were performed before and at the conclusion of administration of the bioactive agent(s). The proliferative rate of the leukemia cells in vivo decreased in four of five patients receiving RA+IFN whereas in one patient proliferation accelerated. The proliferative rate of AML cells accelerated in three of the five patients who received rhGM-CSF and slowed in two patients. These data show that while the proliferative rate of AML cells can be altered in vivo, the effect produced by bioactive agents may be the opposite of the desired effect. Furthermore, the studies described here demonstrate the usefulness of marrow biopsies for measuring the percent S-phase cells and the importance of measuring the duration of S phase so that the effects of bioactive agents on the cell cycle time of the leukemia cells can be determined.</jats:p>", "DOI": "10.1182/blood.v80.10.2600.bloodjournal80102600", "type": "journal-article", "created": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T06:20:28Z", "timestamp": 1570947628000}, "page": "2600-2603", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients"], "prefix": "10.1182", "volume": "80", "author": [{"given": "HD", "family": "Preisler", "sequence": "first", "affiliation": [{"name": "Department of Internal Medicine, University of Cincinnati, OH."}]}, {"given": "A", "family": "Raza", "sequence": "additional", "affiliation": [{"name": "Department of Internal Medicine, University of Cincinnati, OH."}]}, {"given": "RA", "family": "Larson", "sequence": "additional", "affiliation": [{"name": "Department of Internal Medicine, University of Cincinnati, OH."}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "http://ashpublications.org/blood/article-pdf/80/10/2600/224404/2600.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/blood/article-pdf/80/10/2600/224404/2600.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T04:10:23Z", "timestamp": 1574223023000}, "score": 27.479233, "issued": {"date-parts": [[1992, 11, 15]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1992, 11, 15]]}, "issue": "10"}, "URL": "http://dx.doi.org/10.1182/blood.v80.10.2600.bloodjournal80102600", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T10:20:23Z", "timestamp": 1574504423548}, "reference-count": 0, "publisher": "F1000 Research Ltd", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2008, 9, 26]]}, "DOI": "10.3410/f.1120092.579813", "type": "dataset", "created": {"date-parts": [[2012, 9, 18]], "date-time": "2012-09-18T01:36:11Z", "timestamp": 1347932171000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Faculty of 1000 evaluation for Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia."], "prefix": "10.3410", "author": [{"given": "Richard", "family": "Larson", "sequence": "first", "affiliation": []}, {"given": "Toyosi", "family": "Odenike", "sequence": "additional", "affiliation": []}], "member": "2560", "content-created": {"date-parts": [[2008, 9, 17]]}, "container-title": ["F1000 - Post-publication peer review of the biomedical literature"], "deposited": {"date-parts": [[2012, 9, 18]], "date-time": "2012-09-18T01:37:03Z", "timestamp": 1347932223000}, "score": 27.16018, "issued": {"date-parts": [[2008, 9, 17]]}, "references-count": 0, "URL": "http://dx.doi.org/10.3410/f.1120092.579813"}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:18:45Z", "timestamp": 1575530325492}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "12", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[1993, 12, 15]]}, "abstract": "<jats:p>Chromosome band 11q23 is frequently involved in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) de novo, as well as in myelodysplastic syndromes (MDS) and lymphoma. Five percent to 15% of patients treated with chemotherapy for a primary neoplasm develop therapy-related AML (t-AML) that may show rearrangements, usually translocations involving band 11q23 or, less often, 21q22. These leukemias develop after a relatively short latent period and often follow the use of drugs that inhibit the activity of DNA-topoisomerase II (topo II). We previously identified a gene, MLL (myeloid-lymphoid leukemia or mixed-lineage leukemia), at 11q23 that is involved in the de novo leukemias. We have studied 17 patients with t-MDS/t-AML, 12 of whom had cytogenetically detectable 11q23 rearrangements. Ten of the 12 t-AML patients had received topo II inhibitors and 9 of these, all with balanced translocations of 11q23, had MLL rearrangements on Southern blot analysis. None of the patients who had not received topo II inhibitors showed an MLL rearrangement. Of the 5 patients lacking 11q23 rearrangements, some of whom had monoblastic features, none had an MLL rearrangement, although 4 had received topo II inhibitors. Our study indicates that the MLL gene rearrangements are similar both in AML that develops de novo and in t-AML. The association of exposure to topo II- reactive chemotherapy with 11q23 rearrangements involving the MLL gene in t-AML suggests that topo II may play a role in the aberrant recombination events that occur in this region both in AML de novo and in t-AML.</jats:p>", "DOI": "10.1182/blood.v82.12.3705.bloodjournal82123705", "type": "journal-article", "created": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T06:36:49Z", "timestamp": 1570948609000}, "page": "3705-3711", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 5, "title": ["Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA- topoisomerase II"], "prefix": "10.1182", "volume": "82", "author": [{"given": "HJ", "family": "Super", "sequence": "first", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "NR", "family": "McCabe", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "MJ", "family": "Thirman", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "RA", "family": "Larson", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "MM", "family": "Le Beau", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "J", "family": "Pedersen-Bjergaard", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "P", "family": "Philip", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "MO", "family": "Diaz", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "JD", "family": "Rowley", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "http://ashpublications.org/blood/article-pdf/82/12/3705/227311/3705.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/blood/article-pdf/82/12/3705/227311/3705.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T03:41:44Z", "timestamp": 1574221304000}, "score": 27.120514, "issued": {"date-parts": [[1993, 12, 15]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1993, 12, 15]]}, "issue": "12"}, "URL": "http://dx.doi.org/10.1182/blood.v82.12.3705.bloodjournal82123705", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:25:10Z", "timestamp": 1575530710552}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "12", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[1993, 12, 15]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Chromosome band 11q23 is frequently involved in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) de novo, as well as in myelodysplastic syndromes (MDS) and lymphoma. Five percent to 15% of patients treated with chemotherapy for a primary neoplasm develop therapy-related AML (t-AML) that may show rearrangements, usually translocations involving band 11q23 or, less often, 21q22. These leukemias develop after a relatively short latent period and often follow the use of drugs that inhibit the activity of DNA-topoisomerase II (topo II). We previously identified a gene, MLL (myeloid-lymphoid leukemia or mixed-lineage leukemia), at 11q23 that is involved in the de novo leukemias. We have studied 17 patients with t-MDS/t-AML, 12 of whom had cytogenetically detectable 11q23 rearrangements. Ten of the 12 t-AML patients had received topo II inhibitors and 9 of these, all with balanced translocations of 11q23, had MLL rearrangements on Southern blot analysis. None of the patients who had not received topo II inhibitors showed an MLL rearrangement. Of the 5 patients lacking 11q23 rearrangements, some of whom had monoblastic features, none had an MLL rearrangement, although 4 had received topo II inhibitors. Our study indicates that the MLL gene rearrangements are similar both in AML that develops de novo and in t-AML. The association of exposure to topo II- reactive chemotherapy with 11q23 rearrangements involving the MLL gene in t-AML suggests that topo II may play a role in the aberrant recombination events that occur in this region both in AML de novo and in t-AML.</jats:p>", "DOI": "10.1182/blood.v82.12.3705.3705", "type": "journal-article", "created": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T20:23:41Z", "timestamp": 1570998221000}, "page": "3705-3711", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 26, "title": ["Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA- topoisomerase II"], "prefix": "10.1182", "volume": "82", "author": [{"given": "HJ", "family": "Super", "sequence": "first", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "NR", "family": "McCabe", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "MJ", "family": "Thirman", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "RA", "family": "Larson", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "MM", "family": "Le Beau", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "J", "family": "Pedersen-Bjergaard", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "P", "family": "Philip", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "MO", "family": "Diaz", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}, {"given": "JD", "family": "Rowley", "sequence": "additional", "affiliation": [{"name": "Department of Molecular Genetics and cell Biology, University of Chicago, IL 60637."}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "http://ashpublications.org/blood/article-pdf/82/12/3705/610761/3705.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/blood/article-pdf/82/12/3705/610761/3705.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T10:36:21Z", "timestamp": 1574246181000}, "score": 27.120514, "issued": {"date-parts": [[1993, 12, 15]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1993, 12, 15]]}, "issue": "12"}, "URL": "http://dx.doi.org/10.1182/blood.v82.12.3705.3705", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:16:40Z", "timestamp": 1575530200481}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "5", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[1991, 3, 1]]}, "abstract": "<jats:p>The effects of competitive inhibition of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase by compactin on the in vitro proliferation of peripheral blood myeloid leukemia cells were studied using the cells from 45 patients with acute myeloid leukemia or chronic myelogenous leukemia in blast phase. The cells from 58% of these patients showed a dose-related inhibition of DNA synthesis when incubated with compactin. Unexpectedly, cells from 18% of the patients were resistant to the inhibitory effects of compactin on DNA synthesis and responded to the HMG CoA reductase inhibition with an actual increase in the incorporation of 14C-labeled thymidine into DNA. Another 18% of the patients studied displayed both inhibition and stimulation of DNA synthesis in a biphasic response depending on the particular concentration of compactin used. The maximum enhanced rates of cellular DNA synthesis were observed with lower compactin concentrations (5 x 10(-7) mol/L) than were required for maximum inhibition of DNA synthesis (10(-5) mol/L). Leukemia cells displaying a stimulated response to compactin had a significantly lower baseline DNA synthetic rate than did cells that showed an inhibitory response of DNA synthesis to compactin. There was no correlation between these cells' varying DNA synthetic response to compactin and measures of baseline HMG CoA reductase activity or acetate conversion to cholesterol. Whereas the observation of cellular DNA synthesis stimulation by HMG CoA reductase inhibition has not been observed in other mammalian cells and seems paradoxical, explanations may emerge in light of our growing knowledge concerning the importance of isoprenylation for the function of certain cell regulatory proteins.</jats:p>", "DOI": "10.1182/blood.v77.5.1064.bloodjournal7751064", "type": "journal-article", "created": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T00:25:10Z", "timestamp": 1570926310000}, "page": "1064-1070", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells"], "prefix": "10.1182", "volume": "77", "author": [{"given": "RJ", "family": "Hohl", "sequence": "first", "affiliation": [{"name": "Department of Medicine, University of Chicago Medical Center, IL."}]}, {"given": "RA", "family": "Larson", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, University of Chicago Medical Center, IL."}]}, {"given": "V", "family": "Mannickarottu", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, University of Chicago Medical Center, IL."}]}, {"given": "S", "family": "Yachnin", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, University of Chicago Medical Center, IL."}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "http://ashpublications.org/blood/article-pdf/77/5/1064/221632/1064.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/blood/article-pdf/77/5/1064/221632/1064.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T23:03:24Z", "timestamp": 1574204604000}, "score": 27.114788, "issued": {"date-parts": [[1991, 3, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1991, 3, 1]]}, "issue": "5"}, "URL": "http://dx.doi.org/10.1182/blood.v77.5.1064.bloodjournal7751064", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}